



INVESTOR PRESENTATION

DISRUPTING THE VARICOSE VEIN MARKET
WITH **SONOVEIN®**

May 2024

EXECUTIVE SUMMARY

- **New Therac tion story:** New team, new product, new strategy and new business model
- **Disruptive approach in varicose vein treatment:** SONOVEIN® is totally non invasive
- **A huge market:** Varicose veins affect 1 in 3 adults
- **A proven technology:** 95% reflux free*, zero serious adverse event, 2,300+ veins treated
- **Strategy:** Focus on US, China and product development
- **Blockbuster product ready in <2 years:** R&D, improvements and FDA approval
- **Financials:** SONOVEIN's enhancement to accelerate commercial ramp-up and revenue growth

*2023 FDA feasibility study


VARICOSE VEINS: A WIDESPREAD CONDITION

WHAT ARE VARICOSE VEINS?

Varicose veins are swollen, twisted subcutaneous veins of the lower leg


Inadequacy of the valves results in reflux of blood in the veins

ONE IN THREE ADULTS



31% of adults aged 18 to 64 are affected by varicose veins

Source: Maurins et al., 2008



Source: Austin Vein Specialists

THERACLION NEW STORY

A DISRUPTIVE TREATMENT OF VARICOSE VEINS

TWO MAIN CURRENT METHODS

STRIPPING
INVASIVE ++



Surgery
Ripping the vein off

ENDOVENOUS
INVASIVE +



Laser, Radiofrequency,
Cyanoacrylate glue
*Burning or gluing from the
inside through a catheter*

STRESSFUL & RISKY

Anesthesia
Surgery
Sterile environment needed

Potential serious
adverse events

SONOVEIN®
VERY LOW RISK



**NO
SURGERY
NEEDED**

**NO
INCISION**

NON INVASIVE

- No serious adverse event to date
- Quick walk-in walk-out procedure
- One operator only
- Data collection-capability & AI automation potential

THERACLION NEW STORY

SONOVEIN[®], A NEW ROBOTIC SOLUTION




Robotic treatment head with in-line visualization

Robotized
head

Consumable:
Cooling and coupling
Technology (through
Epack[™])

Ultrasound imaging probe

HIFU transducer



Millimetric treatment accuracy

Real-time
ultrasound
visualization and
control



[Video link](#)

INTELLECTUAL PROPERTY

Patents : 164 granted, 211 filed, 30 families in HIFU procedure safety & efficacy, system design and application

BASED ON THERMAL ABLATION


FROM PRINCIPLE...

ULTRASOUND : FOCUSED ACOUSTIC WAVES

- A treatment from outside: no incision
- High Intensity Focused Ultrasound (HIFU)


Spherical transducer

Concentrates
ultrasound wave
to the focal point



... TO APPLICATION

THERACLION'S SONOVEIN FOR VARICOSE VEINS



- Step by step treatment, **moving along** the vein and burning it
- **Robot-driven** movements
- Real-time **ultrasound visualization** and control

VARICOSE VEINS: A MULTIBILLION \$ MARKET POTENTIAL

ALIGNED WITH CURRENT MARKET TRENDS



\$13B

Current medical costs for varicose vein treatments worldwide



5M+

Annual addressable procedures



Up to 50%

Sonovein device cost per procedure

vs:

- Stripping: 1-2%
- Endovenous: 10-15%



SIGNIFICANT GROWTH DRIVERS AND OPPORTUNITIES

- **6,5% annual growth** in varicose veins patients driven by
① Age ② Obesity ③ Lifestyle

- **54% of undiagnosed patients** in industrialized countries
- Largely **unmet medical need** in emerging countries + China

- **50% of people afraid of surgery**
→ untapped patient pool for Sonovein

FROM ECHOPULSE TO SONOVEIN

DEVELOPMENT

2004 to 2018
ECHOPULSE®



Niche markets
**HIFU for thyroid and
fibroadenoma**

4,000+ TREATMENTS

ACCELERATION

2019
SONOVEIN®



2020-2021
SONOVEIN® S



and S+

Large markets
HIFU for veins

2022-2023
SONOVEIN® HD



and HD'23 UPG

ONE PRODUCT UPDATE/YEAR

Treatment time ↓
Ergonomic/easy to use ↑

PROOF OF CONCEPT

EFFECTIVE AND SAFE TREATMENT OF VARICOSE VEINS



OVER 2,300 VEIN TREATMENTS TO DATE

- 95% reflux-free*
- 0 severe adverse event**



+ 18 SITES IN OPERATION IN 12 COUNTRIES

- Top centers at more than 100 treatments/year



+ CE MARKING OBTAINED IN 2019

Latest generation of Sonovein in the process to obtain the new MDR CE marking



+ FDA FEASIBILITY STUDY FINALISED FDA Pivotal study started in 2023

//

*The results are as good - if not a little bit **better** - than some of the results with the more traditional technologies. **95%** of patients had a successful healing of the abnormal vein. All patients felt better.*

***SONOVEIN really is the next evolution** of a completely non-invasive, transcutaneous way of treating vein diseases. //*

Dr Steve Elias - January 2023
(FDA first US trial – principal investigator)

PROOF OF CONCEPT AND PRODUCT FINE-TUNING IN EUROPE THANKS TO STRONG KOL* PARTNERSHIPS

PRODUCT REFINEMENT WITH KOL*

- Fine-tuning product, protocols, and business offering
- Real-life field feedback and product needs collection
- Data collection for next AI development
- Different market practices addressed

PROOF OF CONCEPT TODAY- ONGOING RAMP UP

- Tier-1 sites at 100 or 150 treatments per year already
- Commercial relationships and existing recurring revenue
- Start of reimbursement in some countries (Spain, Italy)
- Measured ramp up among KOLs

INTERNATIONAL AWARENESS

- Sonovein's promotion by KOL* in some of the largest European countries: Italy, France, Spain and the UK
- 50+ conferences by 15 KOL and 6 reference scientific papers

A STRONG BASE FOR TAPPING INTO NEW MARKETS

- Solid groundwork for US and China expansion



*: Key Opinion Leaders

THERACLION NEW STORY: NEW STRATEGY FOCUSED ON THE US, CHINA AND R&D (1)



MARKET

- Largest varicose vein market in the world: 45%
- High price market
- Homogenous access to reimbursement

US MARKET PATH

- Feasibility study completed
- Pivotal study started
- FDA clearance expected early 2026

US TARGETS

- Reach 300 high volume medical centers (200 treatments/year) at \$1,200, i.e. \$72m annual revenue
- Reach \$400m-500m annual revenue at maturity



MARKET

- Largest potential varicose vein market in Asia
- Underserved market that could move directly to Sonovein's non-invasive solution to reach so far untreated patients

CHINESE MARKET PATH & PARTNERSHIP WITH FURUI

- Domestic product development and market access via Furui
- Global manufacturing
- JV's products sold only in China

NEXT MILESTONES

- Joint-Venture with Furui
- Prototyping
- Registration
- Clinical trial start (1.5-3 years)

THERACLION NEW STORY: NEW STRATEGY FOCUSED ON THE US, CHINA AND R&D (2)

Finalizing BLOCKBUSTER PRODUCT in 2 years



ACCELERATE TREATMENT TIME

From: 1h to 1.5h

Down to: 45min or **30min**



IMPROVE EASE OF USE

From: a device for an ultrasound trained medical doctor

Down to: an AI-guided, intuitive device for a non-specialist



INCREASE ADDRESSABLE PATIENT POPULATION

From: mostly great saphenous* vein

Up to: more types of veins, larger, deeper



KEY ENABLERS

AI

ACOUSTICS

ROBOTICS

CLINICAL PRACTICE

MEASURED COMMERCIAL RAMP-UP IN THE TWO COMING YEARS DESPITE STRONG INCOMING DEMAND

GRADUAL RAMP-UP UNTIL FULL MARKET ROLL OUT WITHIN 2 YEARS

SONOVEIN TO THE MARKET: A RIGOROUS PATH

	'23	'24	'25	'26	'27 onwards
US access (FDA)	Pivotal Study starts	Final treatments (Mid 2024)	Final Results (Mid 2025)	FDA Clearance	
China (Furui JV)	Partnership construction	Successful prototyping	Manufacturing capability Trial initiation	Global manufacturing platform Clinical trial	NMPA clearance
Europe	Partnerships 1/ refine product, protocol, business model; 2/ boost Sonovein awareness (KOL) 3) commercial ramp-up			Full speed commercial launch	
Technology	AI bricks	AI + Robotics+ acoustics new bricks	New robotic + AI product on human	New industrialized platform w/ robotics + AI + acoustics	Full automated AI guided device
Reimbursement				Process start in the US	Europe: facilitated by US data

Estimated expectations

THERACLION NEW STORY: A NEW MANAGEMENT TEAM



A SKILLED & DYNAMIC NEW MANAGEMENT TEAM (2022-2024)...



Martin Deterre, PhD
CEO (May 2023)

15y. exp
Pixium Vision, Livanova
M.I.T., Polytechnique
Theraclion since Dec. 2020



Ling-Ling Chea
Chief Financial Officer (Apr. 2024)

20y. exp
Lab. Poupina, Swania,
McGregor, Sodial



Yann Duchesne
Executive Chairman

McKinsey 20y.
Private Equity 13y.
Theraclion since Jan. 2022

... SUPPORTED BY A STABLE AND EXPERIENCED TEAM



Michel Nuta, MD
VP Veins & Chief Medical Officer

30+y. exp
THC since Jan. 2013



Jérémie Anquez, PhD
VP Research & Chief Scientific Officer

15+y. exp
Telecom ParisTech
THC since June 2010



Vivien Jourdainaud
VP QARA

10y. exp
Mauna KEA
THC since Oct. 2015



Gaylord Tallec, PhD
VP Operations

15y. exp
CEA, lifesearch
THC since Sept. 2016



Marie Berne
Marketing Director

10y. exp
Dior, Figaret, EM Lyon
THC since Oct. 2021





29 employees based
in Paris, France
23 engineers, 6 PhD,
1 PharmD, 1 MD

THERACLION NEW STORY

NEW BUSINESS MODEL, PAY-PER-USE

RECURRING REVENUES YEAR ON YEAR VERSUS 1-OFF REVENUES



* To medical centers, hospitals, clinics

P&L: NET LOSS OF €3,7 M, DOWN €1,3 M

LOW SEASONALITY LEVEL OF R&D SPEND

En €K	31/12/2022	31/12/2023	Var. %
Turnover	1 235	1 822	48%
Other Products	132	2 095	1490%
Total Revenues	1 367	3 917	187%
COGS (purchase and stocks variation)	466	331	-29%
External charges	3 820	2 573	-33%
Personnel charges	3 102	3 153	2%
Other operational Charges	287	1 014	253%
Total operating expenses	7 675	7 070	-8%
Operating result	-6 308	-3 153	-50%
Financial result	-8	-1 955	23179%
non recurring result	350	384	10%
R&D tax credit	-1 002	-1 049	5%
Net result	-4 964	-3 675	-26%

Decrease of €1,2 M

- Costs decrease and containment in H1 2023: €0,8 M
- R&D seasonality: 0,4 M€ linked with preliminary feasibility study for FDA extra charges in 2022 and pivotal study starting late 2023 with limited costs impact in 2023

- Includes depreciations (€559K)

Depreciation of APAC subsidiary equity and receivables : €1,9 M

BALANCE SHEET 2023

K€	12/31/2022	12/31/2023	Variation
Non-current assets	4 583	2 542	-2 041
Including intangible assets	1 297	1 225	-72
Including tangible assets	127	106	-21
Of which non-current financial assets	3 159	1 211	-1 948
Current assets	9 360	16 122	6 762
Inventory	3 055	3 055	0
Cash and cash equivalent	2 520	7 815	5 295
Other assets	3 772	5 252	1 480
Total Asset	13 943	18 664	4 721
Equity	545	5 647	5 102
Non current liabilities	6 537	6 290	-247
Including advances from BPI	6 290	6 290	0
Current liabilities	6 861	6 727	-134
Incl. Accruals for Risk & Curr. Exposure	25	215	190
Incl. Loans (PGE)	2 506	1 947	-559
Total Liabilities	13 943	18 664	4 721

Theraclion APAC
equity & receivables
depreciation : 1,9 M€

- Capital raise: 8,7M€
- Cash burn: 3 M€

- Impact of 2 M€
license fees to JV,
payable in 2024


- Capital raise: 8,7 M€
- Net loss offset: 3,7
M€

THERACLION NEW STORY

NEW SHAREHOLDING STRUCTURE

SHAREHOLDERS

(as of December 31st, 2023)



ALTHE

FURUI (300049:CH): GENUINE STRATEGIC PARTNERSHIP

- Theraclion's investor since 2016
- China JV created in 2017
- Replication of Echosens' Success:
 - **Echosens (France):** +/-300 employees, global leader in non-invasive liver diagnostics.
 - **Furui lead development in China,** supports R&D in France and global commercial deployment.
 - Echosens China is a **key contributor to Echosens Global P&L.**

SONOVEIN SUCCESS IN VARICOSE VEINS WILL OPEN THE WAY TO OTHER THERAPIES

VARICOSE VEINS

Build platform

Succeed 1st commercial
breakthrough

THYROID NODULES

\$3.6B market
1,800,000 annual thyroid
nodules surgeries WW

Theraclion's
historical market

Latest Vein platform can
disrupt the Thyroid market

BREAST CANCER

\$20B market, strong growth

Huge potential for HIFU
combined with traditional
therapies: immunology or
chemotherapy

Clinical studies ongoing at
University of Virginia with
Theraclion's device

MORE INDICATIONS

Hyperthermia - Possibility
to heat cancer tissue
locally prior to
radiotherapy

Research programs ongoing

Other indications



- **HIFU:** High Intensity Focused Ultrasound is a non-invasive therapeutic technique that uses non-ionizing ultrasonic waves to heat or ablate tissue.
- **Venous reflux or Chronic Venous Insufficiency (CVI):** occurs when veins no longer circulate blood properly. It often affects the leg veins, causing blood to pool and leading to swelling and discomfort.
- **Serious Adverse Events (SAE):** an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.
- **CEAP classification:** the CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification is an internationally accepted standard for describing patients with chronic venous disorders
- **FDA:** Food and Drug Administration

DISCLAIMER

This presentation does not constitute an offer to sell or a solicitation of a THERACLION share purchase offer.

Some information in this document may include projections and forecasts. THERACLION believes that these forward-looking statements are based on reasonable assumptions as at the date of this document, which are subject to numerous risks and uncertainties. As a result, the numbers and ratings provided may differ significantly from the projected figures. THERACLION neither undertakes nor has the obligation to update the forward-looking information contained in this presentation to reflect any unforeseen event or circumstance occurring after the date of this presentation.

The information contained in this document has been selected by the Group's General Management to present THERACLION and THERACLION's results. This document has not been independently verified. THERACLION makes no commitment as to the accuracy or completeness of this information. None of THERACLION's representatives can be held responsible for any loss resulting from the use of this presentation or its content.

Under no circumstances will THERACLION assume any responsibility for any investment or other decisions made on the basis of the information provided in this presentation. Readers are advised to review the company's financial information and the applicable AMF filings of the company before making any investment or other decision.

FOLLOW US ON LINKEDIN FOR UPDATES



<https://www.linkedin.com/company/theraction/>

THERACLION

244 av. Pierre Brossolette
92240 Malakoff


T +33 1 55 48 90 70

E contact@theraction.com

APPENDICES

VARICOSE VEINS: A WIDESPREAD CONDITION


A STRONG MEDICAL NEED



THE VENOUS SYSTEM

Superficial compartment
Cosmetic impact

Saphenous compartment
Often incompetent



Deep venous system
Main venous stream

Treatment options

SONOVEIN


Sclerotherapy – mini-invasive

Endovenous – mini-invasive

Stripping – invasive

FOCUS ON SHORTENING TREATMENT DURATION

STANDARD GREAT SAPHENOUS VEIN OVERALL TREATMENT DURATION



PUBLICATIONS & PRESENTATIONS ABOUT SONOVEIN®

REFERENCE PUBLICATIONS

INSTITUTION	AUTHOR	TITLE AND REFERENCE	YEAR
Phlebology	Prof. Paolo Casoni	High Intensity Focused Ultrasound in treating great saphenous vein incompetence: Perioperative and 1-year outcomes DOI: 10.1177/02683555241243161	2024
Clinical, Cosmetic and Investigational Dermatology	Prof. Mark Whiteley	Current Best Practice in Management of Varicose Veins DOI: 10.2147/CCID.S294990	2023
College of Phlebology UK	Prof. Mark Whiteley	One Year results of treatment of incompetent truncal veins and incompetent perforators using 8- and 4-seconds pulses of HIFU DOI: https://doi.org/10.31219/osf.io/fzc5k	2022
EJVES Vascular Forum	Dr. Alfred Obermayer	Extracorporeal Treatment with High Intensity Focused Ultrasound of an Incompetent Perforating Vein in a Patient with Active Venous Ulcers DOI: 10.1016/j.ejvsf.2020.11.005	2021
Karl Landsteiner Gesellschaft	Dr. Alfred Obermayer	Weltpremiere : Perkutaner Verschluss von insuffizienten Venen mittels Ultraschall (HIFU) <i>[English] World premiere: Percutaneous closure of insufficient veins using ultrasound (HIFU)</i> Link: https://www.karl-landsteiner.at/pdf/LT/Vortrag%2011.%20Landsteiner%20Tag%202020%20Obermayer.pdf	2020
Current Medical Research and Opinion	Prof. Mark Whiteley	High intensity focused ultrasound (HIFU) for the treatment of varicose veins and venous leg ulcers - a new non-invasive procedure and a potentially disruptive technology DOI: 10.1080/03007995.2019.1699518	2019

2024 PRESENTATIONS: 10 events, 9 speakers, 7 countries *(to date)*



EVENT	SPEAKER	TITLE	LOCATION	DATE
American Vein & Lymphatic Society (AVLS) Congress	Prof. Paolo Casoni	tbc	Chicago, US	COMING UP OCTOBER 2024
Congresso Internazionale di Flebologia	Prof. Paolo Casoni	tbc	Bologna, ITALY	COMING UP OCTOBER 2024
Congrès de la Société Française de Médecine Vasculaire (SFMV)	Dr. Guillaume Stalnikiewicz	tbc	Dijon, FRANCE	COMING UP SEPTEMBER 2024
European Venous Forum (EVF) Meeting	Prof. Paolo Casoni	High Intensity Focused Ultrasound in treating great saphenous vein incompetence: perioperative and 1-year outcomes	Athens, GREECE	COMING UP JUNE 2024
	Dr. Emanuele Nanni			
	Dr. Matteo Pizzamiglio			
Benelux Society of Phlebology Congress	Prof. Mark Whiteley	Percutaneous ablation using high-intensity focused ultrasound	Genk, BELGIUM	COMING UP JUNE 2024
Venous Symposium	Dr. Steve Elias	High Intensity Focused Ultrasound: Multicenter Trial	New York, US	MAY 2024
Canadian Society of Phlebology Congress	Dr. Emanuele Nanni	HIFU: How it works and outcomes	Montreal, CANADA	MAY 2024
	Prof. Paolo Casoni			
College of Phlebology UK Masterclass	Prof. Mark Whiteley	Mastering Venous Insufficiency with HIFU: The Ultimate Guide to Sonovein Echotherapy for Optimal Results	Guildford, UK	MAY 2024
	Dr. Guillaume Stalnikiewicz	HIFU: What it is, What it makes, and... What it takes!		
	Dr. Luis Izquierdo Lamoca	HIFU Efficiency in Leak Point Closure in the Chiva Procedure Description and 4 Years Result		
Vein in Venice Symposium	Dr. Guillaume Stalnikiewicz	High Intensity Focused Ultrasound (HIFU): Short- and mid-term results	Venice, ITALY	APRIL 2024
	Dr. Ruben Rodriguez Carvajal	High Intensity Focused Ultrasound		
Find Your Algorithm (FYA) Congress	Prof. Mark Whiteley	Upcoming treatment in venous reflux	London, UK	JANUARY 2024

2023 PRESENTATIONS: 12 events, 10 speakers, 7 countries (part 1)

EVENT	SPEAKER	TITLE	LOCATION	DATE
International Meeting on Aesthetic Phlebology (IMAP)	Prof. Mark Whiteley	New insights into success and failure of Venous Ablation with Sonovein (HIFU) – WINNER OF THE HIROSHI MIYAKE AWARD	Sao Paulo, BRAZIL	DECEMBER 2023
French Society of Phlebology Congress	Dr. Guillaume Stalnikiewicz	Les HIFU sont-ils l'avenir du traitement des varices ? [English] Is HIFU the future of varicose vein treatment?	Paris, FRANCE	DECEMBER 2023
VEITHsymposium	Dr. Steve Elias	HIFU: What Do We Know And Report - Global Report	New York, US	NOVEMBER 2023
Endovascular Foundation SITE Symposium	Prof. Mark Whiteley	Echotherapy for varicose veins. What have we already learnt in last two years? Recorded case - Echotherapy with Sonovein. Advances to date	Barcelona, SPAIN	OCTOBER 2023
	Dr. Luis Izquierdo Lamoca	Spanish experience with echotherapy		
VIVA VEINS	Dr. Steve Elias	SONOVEIN technology presentation	Las Vegas, US	OCTOBER 2023
International Union of Phlebology (UIP) & American Venous Lymphatic Society (AVLS) Congress	Prof. Paolo Casoni	Action of High Intensity Focused Ultrasound (HIFU) on the Venous Wall: Histopathological Analysis	Miami, US	SEPTEMBER 2023
	Prof. Jaroslav Strejček	Innovations in Chronic Venous Disease Treatment		
	Dr. Steve Elias	Other Ablation Techniques Emerging Technology		
		Emerging Technologies: High Intensity Focused Ultrasound - Sonovein		
	Dr. Ferdinand Steinbacher	First 28 patients with Sonovein HD		

2023 PRESENTATIONS: 12 events, 10 speakers, 7 countries *(part 2)*

EVENT	SPEAKER	TITLE	LOCATION	DATE
Egyptian Venous Forum	Dr. Ruben Rodriguez Carvajal	High Intensity Focused Ultrasound	Cairo, EGYPT	JULY 2023
Venous Symposium	Dr. Steve Elias	HIFU: What Do We Know And Report	New York, US	MAY 2023
Leading Innovative Vascular Education (LIVE) Venous Symposium (VS) European Chapter	Dr. Antonios Gasparis	Novel Technologies in Superficial Venous Disease Management	Corfu, GREECE	MAY 2023
European Venous Forum (EVF) Meeting	Dr. Emanuele Nanni	Action of HIFU on the venous wall: Histopathological analysis	Berlin, GERMANY	JUNE 2023
Symposium on Therapeutic Ultrasound	Bjoern Gerold, PhD	CURE-OP: Thermometry for Hyperthermia Treatments	Lyon, FRANCE	APRIL 2023
American Venous Forum (AVF) Congress	Dr. Antonios Gasparis	First In US Sonovein Trial: Final Results	San Antonio, US	FEBRUARY 2023
	Dr. Steve Elias			
	Dr. Ferdinand Steinbacher	First Experience with Sonovein HD		

2022 PRESENTATIONS: 10 events, 8 speakers, 6 countries (part 1)

EVENT	SPEAKER	TITLE	LOCATION	DATE
College of Phlebology UK E-meeting	Prof. Mark Whiteley	Special session dedicated to HIFU	Online UK	DECEMBER 2022
	Prof. Paolo Casoni	What is the HIFU procedure treating varicose veins?		
	Dr. Guillaume Stalnikiewicz	Which patients are the best fit for HIFU procedure?		
	Dr. Teresa Reyero Postigo	Why is Sonovein revolutionary in treating varicose veins?		
French Society of Phlebology	Dr. Guillaume Stalnikiewicz	Traitement non invasif des perforantes incontinentes par échothérapie : série de cas	Paris, FRANCE	DECEMBER 2022
	Dr. Maxime de Deken			
	Prof. Paolo Casoni	HIFU can change phlebology: the Italian experience in 80 cases		
VEITHsymposium	Prof. Mark Whiteley	Truncal Ablation of the Saphenous Venous System	New York, US	NOVEMBER 2022
Focused Ultrasound Foundation International Symposium 2022	Dr. Steve Elias	Top-line results from 20 patients treated with SONOVEIN® HD	Rockville, US	OCTOBER 2022
	Dr. Ruben R. Carvajal	Preliminary results on 47 patients treated with SONOVEIN® S		
VIVA VEINS	Dr. Steve Elias	First patients treated with SONOVEIN®	Las Vegas, US	OCTOBER 2022

2022 PRESENTATIONS: 10 events, 8 speakers, 6 countries (part 2)

EVENT	SPEAKER	TITLE	LOCATION	DATE
American Vein & Lymphatic Society (AVLS)	Dr. Steve Elias	HIFU for Great Saphenous Vein Incompetence: First Initial US Expérience and Results	New Orleans, US	OCTOBER 2022
Spanish Society For Surgical Research	Dr. Teresa Reyero Postigo	High Intensity Focused Ultrasound for Varicose Veins	Gijón, SPAIN	SEPTEMBER 2022
Congrès de la Société Française de Médecine Vasculaire (SFMV)	Dr. Maxime de Deken	Traitement non-invasif des veines perforantes incontinentes par échothérapie : série de cas	Toulouse, FRANCE	SEPTEMBER 2022
International Union of Phlebology (UIP) Congress	Prof. Mark Whiteley	Thermal, nonthermal or HIFU in 2022	Istanbul, TURKEY	SEPTEMBER 2022
	Prof. Paolo Casoni	HIFU how ultrasounds can change phlebology: the Italian experience in 80 cases		
	Prof. Jaroslav Strejček	HIFU: a revolutionary step on the way to non-invasive treatment of varicose veins		
	Dr. Teresa Reyero Postigo	HIFU Efficiency in leak point closure in the conservative hemodynamic treatment of venous insufficiency		
Swiss Vein days	Dr. Guillaume Stalnikiewicz	Sonovein treatments results: 95% occlusion rate	Bruderholz, SWITZERLAND	JUNE 2022

2021 PRESENTATIONS: 7 events, 3 speakers, 6 countries

EVENT	SPEAKER	TITLE	LOCATION	DATE
VEITHsymposium	Prof. Mark Whiteley	HIFU: Is it ready for Prime Time? Tips, Tricks and Limitations: HIFU	Orlando, US	NOVEMBER 2021
Paris Vascular Insights	Prof. Mark Whiteley	Treatment of saphenous veins with HIFU	Paris, FRANCE	OCTOBER 2021
Egyptian Venous Forum	Prof. Mark Whiteley	Stop surgery and go HIFU for the treatment of varicose veins	Alexandria, EGYPT	OCTOBER 2021
Congresso Internazionale di Flebologia	Prof. Paolo Casoni	HIFU (High Intensity Focused Ultrasound): how ultrasounds can change phlebology: mechanism of action and future indications	Bologna, ITALY	SEPTEMBER 2021
Congrès de la Société Française de Médecine Vasculaire (SFMV)	Dr. Maxime de Deken	Innovation thérapeutique dans la maladie veineuse chronique : premiers résultats de l'échothérapie ou traitement par ultrasons focalisés de haute intensité (HIFU) échoguidés	Cannes, FRANCE	SEPTEMBER 2021
Kazakhstan Venous Forum	Prof. Mark Whiteley	Early results of Sonovein and Sonovein S (High Intensity Focused Ultrasound) treatment of varicose veins	Online KHAZAKHSTAN	MAY 2021
Venous Association of India Conference (VAICON)	Prof. Mark Whiteley	Sonovein and Sonovein S – How I do it	Online INDIA	JANUARY 2021

2019-20 PRESENTATIONS: 13 events, 1 speaker, 9 countries

EVENT	SPEAKER	TITLE	LOCATION	DATE
16 th UCCVS	Prof. Mark Whiteley	The Latest and Most Revolutionary Echotherapy Treatment for Varicose Veins and Venous Leg Ulcers: SONOVEIN	Antalya, TURKEY	OCTOBER 2020
International Union of Phlebology (UIP) Webinar	Prof. Mark Whiteley	HIFU – The Good, the Bad and The Ugly	Online	AUGUST 2020
American Vein & Lymphatic Society (AVLS) Congress	Prof. Mark Whiteley	Six months outcomes from high intensity focused Ultrasound (HIFU) closure of incompetent saphenous and perforator veins	Online US	JULY 2020
SBACVES Sociedade	Prof. Mark Whiteley	High Intensity Focused Ultrasound (HIFU) closure of Varicose Veins – Echotherapy (Sonovein)	Online BRAZIL	JULY 2020
EgyVasc Virtual Conference	Prof. Mark Whiteley	Is HIFU the future of Varicose Veins Ablation?	Online EGYPT	JUNE 2020
IMAP X Live 2020	Prof. Mark Whiteley	Is HIFU the future of Varicose Veins Ablation?	Online BRAZIL	MAY 2020
Sonovein Echotherapy Webinar	Prof. Mark Whiteley	Echotherapy Treatment of Varicose Veins using Sonovein (HIFU)	Online UK	APRIL 2020
Venous Association of India Conference (VAICON)	Prof. Mark Whiteley	Description of a new technique: Sonovein Indications and Results	Mumbai, INDIA	JANUARY 2020
Controversies & Updates in Vascular Surgery (CACVS)	Prof. Mark Whiteley	Description of a new technique the Sonovein: indications, results	Paris, FRANCE	JANUARY 2020
Society Vascular Technologists (SVT) Meeting	Prof. Mark Whiteley	The role of ultrasound and the vascular technologist in High Intensity Focused Ultrasound (HIFU) treatment for venous incompetence – 1ST PRIZE WINNER	Manchester, UK	NOVEMBER 2019
American Vein & Lymphatic Society (AVLS) Congress	Prof. Mark Whiteley	High Intensity Focused Ultrasound (HIFU) in the Treatment of Incompetent Superficial Veins and Perforating Veins: a Report of our Early Experience – 2ND PRIZE WINNER	Phoenix, US	NOVEMBER 2019
Middle East Venous Forum	Prof. Mark Whiteley	Early report of High Intensity Focused Ultrasound (HIFU) in the treatment of varicose veins	Abu Dhabi, UAE	OCTOBER 2019
Northern European Endovenous Forum (NEEF)	Prof. Mark Whiteley	Novel thermal techniques for the treatment of superficial venous reflux - Endovenous Microwave Ablation (EMWA) and High Intensity Focused Ultrasound (HIFU)	Riga, LATVIA	AUGUST 2019